Inventor · disambiguated record
Peter Rands
Also filed as: RANDS PETER
14 granted patents·12 pending applications·66 citations·filing 2017–2025
90Inventor score
Top patents by PatentIndex Score
26 records- 0195US11773062B2Deuterated compoundsSMALL PHARMA LTD·Filed 2021·Granted Oct 3, 2023·9 cites·7 claims
- 0295US11660289B2Deuterated or partially deuterated N,N-dimethyltryptamine compoundsSMALL PHARMA LTD·Filed 2022·Granted May 30, 2023·11 cites·15 claims
- 0395US11643390B2Synthesis of N,N-dimethyltryptamine-type compounds, methods, and usesSMALL PHARMA LTD·Filed 2021·Granted May 9, 2023·9 cites·20 claims
- 0495US11578039B2CompoundsSMALL PHARMA LTD·Filed 2022·Granted Feb 14, 2023·9 cites·14 claims
- 0595US11471417B2Deuterated N,N-dimethyltryptamine compoundsSMALL PHARMA LTD·Filed 2021·Granted Oct 18, 2022·16 cites·12 claims
- 0694US11697638B25-methoxy-N,N-dimethyltryptamine crystalline formsSMALL PHARMA LTD·Filed 2021·Granted Jul 11, 2023·10 cites·19 claims
- 0791US12157723B2CompoundsCYBIN UK LTD·Filed 2023·Granted Dec 3, 2024·1 cites·20 claims
- 0885US2025042852A1CompoundsCYBIN UK LTD·Filed 2024·Application pending·0 cites
- 0984US2024217929A1Synthesis of n,n-dimethyltryptamine-type compounds, methods, and usesCYBIN UK LTD·Filed 2024·Application pending·0 cites
- 1081US12084417B2Synthesis of N,N-dimethyltryptamine-type compounds, methods, and usesCYBIN UK LTD·Filed 2023·Granted Sep 10, 2024·0 cites·19 claims
- 1179US11771681B2Therapeutic compoundsSMALL PHARMA LTD·Filed 2020·Granted Oct 3, 2023·1 cites·9 claims
- 1275US12251371B2Deuterated or partially deuterated N,N-dimethyltryptamine compoundsCYBIN UK LTD·Filed 2023·Granted Mar 18, 2025·0 cites·19 claims
- 1374US2024374565A1Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compoundsCYBIN UK LTD·Filed 2024·Application pending·0 cites
- 1469US12042564B2Therapeutic solid dosage formsCYBIN UK LTD·Filed 2021·Granted Jul 23, 2024·0 cites·21 claims
- 1565US12076311B2Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compoundsCYBIN UK LTD·Filed 2020·Granted Sep 3, 2024·0 cites·20 claims
- 1665US2024342101A1Therapeutic solid dosage formsCYBIN UK LTD·Filed 2024·Application pending·0 cites
- 1762US2022306569A1Crystalline forms of hydroxynorketamineSMALL PHARMA LTD·Filed 2022·Application pending·0 cites
- 1862US2024325351A1Method of administrationCYBIN UK LTD·Filed 2024·Application pending·0 cites
- 1958US12318477B2Injectable and inhalable formulationsCYBIN UK LTD·Filed 2022·Granted Jun 3, 2025·0 cites·21 claims
- 2058US11377416B2Crystalline forms of hydroxynorketamineSMALL PHARMA LTD·Filed 2018·Granted Jul 5, 2022·0 cites·4 claims
- 2157US2025032450A1Injectable and inhalable formulationsCYBIN UK LTD·Filed 2022·Application pending·0 cites
- 2251US2022169606A1Compositions and compounds for bioanalysisSMALL PHARMA LTD·Filed 2020·Application pending·0 cites
- 2349US2022168274A1Parenteral FormulationSMALL PHARMA LTD·Filed 2020·Application pending·0 cites
- 2448US2025262145A1Injectable and inhalable formulationsCYBIN UK LTD·Filed 2025·Application pending·0 cites
- 2543US2021315840A1Solid oral dosage forms of ketamine derivativesSMALL PHARMA LTD·Filed 2018·Application pending·0 cites
- 2640US2019380978A1Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereofSMALL PHARMA LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Rands files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →